Omega-3 fatty acids—especially EPA and DHA—are well known for their cardiovascular benefits. They lower triglycerides, reduce inflammation, and support vascular health. But studies over the last few years have raised questions about whether omega-3 supplements might increase the risk of atrial fibrillation (AF), the most common heart rhythm disorder.

What the Research Shows

A 2021 meta-analysis from the American Heart Association reviewed over 80,000 participants from major cardiovascular trials. Researchers found a small, dose-dependent increase in AF among those taking omega-3 supplements—primarily at higher doses (≥1 g/day).

At lower doses (≤1 g/day), this association was minimal or not statistically significant. Even when present, the absolute risk increase was small—typically fewer than 10 additional AF cases per 1,000 people over several years.

Why Results Differ

The relationship between omega-3s and AF isn’t consistent across studies. Differences often depend on:

• Population: Higher AF rates appear in older adults or those with existing cardiovascular disease.

• Formulation: Trials using EPA alone or mixed EPA+DHA show variable effects. Observational research often links higher DHA levels with lower AF risk.

• Dose: Findings suggest a possible U-shaped curve—too little offers limited benefit, while very high doses may slightly increase AF risk in some people.

In other words, both context and dosing matter.

Potential Mechanisms

Omega-3s affect heart rhythm by altering ion channel function and cell membrane stability. At moderate levels, this can help maintain normal rhythm. At very high concentrations, however, electrical conduction may slow slightly, potentially increasing AF risk in susceptible individuals.

Practical Takeaways

Omega-3s remain an important part of cardiovascular and metabolic care. The potential for a small AF signal at higher doses highlights the need for personalized use rather than avoidance.

1. Dose matters. Higher doses (especially 2–4 grams per day) may increase AF risk in some people, while lower doses (≤1 gram) generally do not.

2. Individual context matters. People with prior heart disease, older age, or other AF risk factors may need closer monitoring when taking higher doses.

3. Lifestyle still leads. Maintaining a healthy weight, exercising regularly, moderating alcohol, and not smoking all significantly reduce AF risk—often more than any supplement can.

4. Testing can personalize decisions. Measuring an Omega-3 Index helps identify baseline levels and guides whether supplementation is needed or if current dosing is sufficient.

Why Quality and Form Matter

Not all omega-3 supplements are created equal. Differences in source, form, and processing can influence how effectively the body absorbs and uses them.

• Source: Natural, minimally processed fish oils tend to preserve the fatty acids in their native structure and are less prone to oxidation than highly refined or synthetic products.

• Form: Omega-3s in the triglyceride (TG) or re-esterified triglyceride (rTG) forms are absorbed more efficiently and raise blood levels more consistently than ethyl ester (EE) forms. This slower, steadier absorption pattern may help maintain stable tissue levels of EPA and DHA and reduce the likelihood of rapid shifts in cardiac electrophysiology that could influence arrhythmia risk.

Choosing a high-quality, third-party-tested product in its natural TG form and keeping doses moderate can help optimize outcomes while minimizing potential downsides.

The Bottom Line

Omega-3s continue to play a meaningful role in heart health, particularly for triglyceride management and inflammation. The current research suggests that moderate intake—whether through diet or supplements—supports cardiovascular well-being without significantly raising AF risk.

When used thoughtfully, omega-3s remain a powerful ally for cardiovascular and metabolic health. The key is balance: appropriate dose, high-quality source, and individualized use.

-Carey Kunz, ND, IFMCP

Director of Education at FMP Essentials

References:

1. Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(23):1981-1990. doi:10.1161/CIRCULATIONAHA.121.055654

2. Albert CM, Cook NR, Pester J, Moorthy MV, Ridge C, Danik JS, Gencer B, Siddiqi HK, Ng C, Gibson H, Mora S, Buring JE, Manson JE. Effect of marine omega-3 fatty acid and vitamin D supplementation on incident atrial fibrillation: a randomized clinical trial. JAMA. 2021;325(11):1061-1073. doi:10.1001/jama.2021.1489

3. Wu JH, Lemaitre RN, King IB, Song X, Sacks FM, Rimm EB, Heckbert SR, Siscovick DS, Mozaffarian D. Association of plasma phospholipid long-chain ω-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2012;125(9):1084-1093. doi:10.1161/CIRCULATIONAHA.111.062653

4. Kapoor K, Alfaddagh A, Al Rifai M, Bhatt DL, Budoff MJ, Nasir K, Miller M, Welty FK, McEvoy JW, Dardari Z, Shapiro MD, Blumenthal RS, Tsai MY, Blaha MJ. Association between omega-3 fatty acid levels and risk for incident major bleeding events and atrial fibrillation: MESA. J Am Heart Assoc. 2021;10(11):e021431. doi:10.1161/JAHA.121.021431

5. Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalabeitia E, Baeza C, Aguayo R, Castillo R, Carrasco R, Gormaz JG. A randomized controlled trial to prevent postoperative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol. 2013;62(16):1457-1465. doi:10.1016/j.jacc.2013.07.014

6. Larsson SC, Drca N, Jensen-Urstad M, Wolk A. Combined impact of healthy lifestyle factors on risk of atrial fibrillation: prospective study in men and women. Int J Cardiol. 2016;203:46-49. doi:10.1016/j.ijcard.2015.10.106

7. Wasmer K, Eckardt L, Breithardt G. Predisposing factors for atrial fibrillation in the elderly. J Geriatr Cardiol. 2017;14(3):179-184. doi:10.11909/j.issn.1671-5411.2017.03.010

8. Dyerberg J, Madsen P, Møller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010;83(3):137-141. doi:10.1016/j.plefa.2010.06.007

9. Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D. Steady-state bioavailability of omega-3 acid ethyl esters and re-esterified triglyceride forms. J Clin Lipidol. 2013;7(6):667-674. doi:10.1016/j.jacl.2013.08.003

10. Yurko-Mauro K, Kralovec J, Bailey-Hall E, Smeberg V, Stark JG, Salem N Jr. Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish-oil and krill-oil supplements. Lipids Health Dis. 2014;13:99. doi:10.1186/1476-511X-13-99